Rhumbline Advisers Sells 6,261 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE)

Rhumbline Advisers decreased its holdings in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) by 11.2% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 49,435 shares of the company’s stock after selling 6,261 shares during the period. Rhumbline Advisers’ holdings in Apogee Therapeutics were worth $1,945,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. EntryPoint Capital LLC raised its position in Apogee Therapeutics by 44.7% during the first quarter. EntryPoint Capital LLC now owns 1,997 shares of the company’s stock valued at $133,000 after purchasing an additional 617 shares in the last quarter. Allspring Global Investments Holdings LLC purchased a new stake in Apogee Therapeutics during the second quarter valued at about $143,000. Kennedy Capital Management LLC purchased a new stake in Apogee Therapeutics during the first quarter valued at about $212,000. Principal Financial Group Inc. raised its position in Apogee Therapeutics by 26.3% during the second quarter. Principal Financial Group Inc. now owns 6,442 shares of the company’s stock valued at $253,000 after purchasing an additional 1,340 shares in the last quarter. Finally, Ameritas Investment Partners Inc. raised its position in Apogee Therapeutics by 111.2% during the first quarter. Ameritas Investment Partners Inc. now owns 4,126 shares of the company’s stock valued at $274,000 after purchasing an additional 2,172 shares in the last quarter. Hedge funds and other institutional investors own 79.04% of the company’s stock.

Apogee Therapeutics Stock Down 0.7 %

NASDAQ APGE opened at $52.95 on Friday. The stock’s 50-day simple moving average is $47.64 and its two-hundred day simple moving average is $49.94. Apogee Therapeutics, Inc. has a twelve month low of $14.19 and a twelve month high of $72.29. The company has a market capitalization of $3.10 billion, a price-to-earnings ratio of -10.16 and a beta of 2.75.

Apogee Therapeutics (NASDAQ:APGE) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.60) EPS for the quarter, hitting the consensus estimate of ($0.60). On average, equities analysts expect that Apogee Therapeutics, Inc. will post -2.57 earnings per share for the current fiscal year.

Insider Transactions at Apogee Therapeutics

In related news, insider Carl Dambkowski sold 5,995 shares of the firm’s stock in a transaction dated Wednesday, July 3rd. The stock was sold at an average price of $37.60, for a total value of $225,412.00. Following the sale, the insider now directly owns 294,793 shares of the company’s stock, valued at $11,084,216.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, insider Carl Dambkowski sold 5,995 shares of the firm’s stock in a transaction dated Wednesday, July 3rd. The stock was sold at an average price of $37.60, for a total value of $225,412.00. Following the sale, the insider now directly owns 294,793 shares of the company’s stock, valued at $11,084,216.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Michael Thomas Henderson sold 15,000 shares of the firm’s stock in a transaction dated Friday, July 5th. The stock was sold at an average price of $37.26, for a total value of $558,900.00. Following the completion of the sale, the chief executive officer now directly owns 1,474,487 shares in the company, valued at $54,939,385.62. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 120,995 shares of company stock worth $5,218,774. Company insiders own 36.10% of the company’s stock.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.